- Home
- BROS vs ROIV Comparison
BROS vs ROIV Comparison
Compare BROS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BROS | ROIV |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 14.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BROS | ROIV |
|---|---|---|
| Price | $64.75 | $22.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $77.16 | $24.31 |
| AVG Volume (30 Days) | 3.2M | ★ 8.2M |
| Earning Date | 11-05-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.73 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $1,537,335,000.00 | $20,329,000.00 |
| Revenue This Year | $28.73 | N/A |
| Revenue Next Year | $25.41 | $376.94 |
| P/E Ratio | $128.14 | ★ N/A |
| Revenue Growth | ★ 28.93 | N/A |
| 52 Week Low | $47.16 | $8.73 |
| 52 Week High | $86.88 | $23.47 |
Technical Indicators
Market Signals| Indicator | BROS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 68.89 | 61.61 |
| Support Level | $60.25 | $21.60 |
| Resistance Level | $65.93 | $23.47 |
| Average True Range (ATR) | 1.94 | 0.88 |
| MACD | 0.53 | 0.06 |
| Stochastic Oscillator | 88.64 | 69.09 |
Price Performance
Historical ComparisonAbout BROS Dutch Bros Inc.
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.